 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
Clinical and Administrative
The purpose of the coverage criteria is to distinguish which individuals, present in North Carolina, are eligible for state-supplied vaccine from the North Carolina Immunization Program (NCIP). NCIP state-supplied vaccine is generally available for children through the age of 18 in compliance with recommendations made by the Advisory Committee for Immunization Practices (ACIP) and the Vaccines for Children (VFC) program. ACIP recommends certain vaccines for certain individuals who are not covered by NCIP state-supplied vaccine. Health care providers must use privately-purchased vaccine for those individuals who wish to have vaccine and are not covered by this coverage criteria. For the current recommendations for each vaccine, please see the ACIP statements found at: http://www.cdc.gov/vaccines/pubs/ACIP-list.htm. 
Providers should use this coverage criteria document for all state-supplied vaccine (that is not part of the transition plan) received after June 30, 2010.
Any provider (local health departments and private providers) with transition vaccine should use this coverage criteria document.
Providers who had state-funded, state-supplied vaccine on hand on or before June 30, 2010 should use the June 14, 2010 Coverage Criteria until all doses are administered.
Immediate Expansion of Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccine: Because of increased incidence of pertussis disease (whooping cough) in North Carolina, the NCIP is making Tdap vaccine universally available immediately and until further notice. It is likely that the program will run through next fall. Please refer to the memo dated March 15, 2012 (PDF, 63 KB) for complete details.
Expansion in Availability and Coverage Criteria for State-Supplied Influenza Vaccine: During the 2011-2012 influenza season only, providers may order additional influenza vaccine that may be administered to anyone over 6 months of age, regardless of insurance status. Please refer to the memo dated December 8, 2011 (PDF, 68 KB) for more information.
Availability of Adult Vaccine Changes: As a result of contract changes between the CDC and vaccine manufacturers, providers may no longer use the following NCIP vaccines for patients ages 19 and older: Menactra® (MCV4), Decavac® (Td), and Adacel® (Tdap) effective December 15, 2011. Please refer to the memo dated December 15, 2011 (PDF, 62 KB) for complete details.
Expanded Recommendations for Quadrivalent Meningococcal Conjugate Vaccines: The CDC has updated vaccination recommendations for adolescents and persons at high risk for meningococcal disease. Please refer to the memo dated February 18, 2011 (PDF, 70 KB) for complete details.
Expanded Tdap Recommendations: The Centers for Disease Control and Prevention has expanded recommendations for Tdap to include children 7 through 10 years of age and adults over 65. Please refer to the memo dated February 2, 2011 (PDF, 64 KB) for complete details. In addition, a note was added to indicate, per the manufacturer, no MMRV orders will be taken after February 1, 2011 due to limited supply.
Program Change: Effective July 1, 2010, NCIP providers may no longer order state-supplied vaccine for non-VFC-eligible children. Please refer to the memo dated June 28, 2010 (PDF, 67 KB) for more information.
